A further prominent target for inhibition is PI3K with idelalisib, copanlisib and duvelisib approved for r/r CLL/SLL and FL, the first inhibits selectively PI3kdelta, the latter inhibits PI3Kalpha and PI3Kdelta and the last PI3Kdelta and PI3Kgamma (229–231). Here, PIK3CD is linked to B-cell chronic lymphocytic leukemia.